Twist (TWST) Q2 2026 Earnings Call Transcript

Twist Bioscience reported Q2 revenue of $110.7 million, up 19.3% year over year, with gross margin expanding to 51.6% and adjusted EBITDA loss improving to $13.3 million. Management raised fiscal 2026 revenue guidance to $442 million-$447 million and reiterated a path to adjusted EBITDA breakeven in Q4, while highlighting strong AI-driven therapeutics demand and a new AWS BioDiscovery partnership. The quarter also included an agreement in principle to settle securities litigation for about $17.1 million.

Analysis

TWST is transitioning from a cyclical tools vendor into a higher-quality workflow compounder: the key second-order effect is that AI discovery expands sequence intensity per program, not just customer count. That matters because the business is no longer dependent on a handful of flagship accounts to carry the step-up; broader adoption across pharma, diagnostics, and international geographies lowers concentration risk and makes the growth runway more durable than a single-platform launch story.

The more interesting signal is margin architecture. Management is effectively choosing near-term operating leverage over near-term EBITDA optics, which usually reads as dilutive, but here it is creating a higher-velocity capacity flywheel: better acceptance rates, more products accepted, more wallet share, and more data generation that can be monetized downstream. If execution holds, the market should start valuing TWST less like a low-margin consumables company and more like a platform with expanding attach rate and recurring workflow revenue.

The contrarian risk is that consensus may be overpaying for the AI narrative while underestimating how much of the growth is still tied to experimental budgets and customer-funded project timing. If biotech financing tightens again, the academic/government pressure could offset some of the upside from therapeutics, and the path to breakeven could slip if the company keeps reinvesting aggressively. The setup is strongest over 6-12 months, but the stock likely trades on whether sequential NGS re-acceleration and gross margin stability are visible by the next 1-2 quarters.

Second-order winner/loser dynamics favor enabling platforms that sit inside AI-driven drug discovery workflows; smaller niche vendors with narrower manufacturing envelopes should lose share as customers consolidate vendors. The litigation overhang is now more of a capital allocation issue than a business issue, but it still caps near-term multiple expansion because cash burn remains the bridge to profitability. The key question for the tape is whether investors will pay up for a company that is still reinvesting, or demand proof of self-funding first.

Key Decisions for Investors

• Long TWST into the next 1-2 quarters on pullbacks: the setup is a 6-12 month re-rating trade if sequential growth holds and EBITDA breakeven stays on track. Upside is tied to multiple expansion as the market recognizes improving quality of growth; risk is a sentiment reset if academic demand weakens further.
• Buy TWST Jan-2027 call spreads or call options on weakness: this is the cleanest way to express the thesis that AI-enabled workflow intensity and improved acceptance rates compound over time. Risk/reward favors optionality because the stock likely needs another 1-2 quarters of proof before re-rating fully.
• Pair trade: long TWST / short a narrower life-science tools peer with less exposure to AI discovery workflows and less product breadth. The relative-value case is that TWST is gaining share by being the platform of choice, while niche peers face customer consolidation pressure.
• Avoid chasing the stock after strong gap-ups; use post-earnings consolidation to build exposure. The near-term risk is that investors overinterpret AI-driven demand as linear and get disappointed if project timing creates quarter-to-quarter noise.
• If cash burn does not improve by the next reporting cycle, trim exposure by 20-30%: the equity remains vulnerable until the company proves it can fund growth without recurring dilution or balance-sheet pressure.